Congenital chloride diarrhea (CCD) is a rare autosomal recessive disease, which is characterized by electrolyte absorption defect due to impaired function of the Cl -/ HCO 3 -exchanger in the ileum and the colon. Its main features are profuse watery diarrhea, high fecal chloride concentration, and failure to thrive. Profuse watery diarrhea characterized by a high concentration of chloride in stools results in hypochloremia, hyponatremia, and dehydration with metabolic alkalosis. Early detection and therapeutic intervention can prevent life-threatening symptoms of CCD and growth failure. Recently, several therapies, such as proton pump inhibitors and butyrate, have been suggested for amelioration of diarrhea. Here, we report a case of CCD in a preterm male infant who was successfully treated with an oral proton pump inhibitor.
INTRODUCTION
Congenital chloride diarrhea (CCD) is a rare autosomal recessive disease, which is characterized by defective absorption of chloride in the intestine. In 1945, two cases of this disease, which presented with congenital diarrhea and metabolic alkalosis, were described for the first time by Gamble and Darrow 1, 2) . To date, more than 250 CCD cases have been reported worldwide 3) . The incidence in Finland is approximately 1:30,000 to 1:40,000, accounting for approximately one-fifth of the reported cases 3) . Higher incidence (>1:20,000) was reported in patients from Poland, Kuwait, and Saudi Arabia 3, 4) . The incidence of CCD in Korea and other East Asian countries has not been evaluated thus far and only a few CCD cases have been reported 5) . CCD is caused by mutations in the solute carrier family 26 member 3 gene (SLC26A3) located on chromosome 7q31, which encodes the transmembrane Cl -/HCO3 -exchanger present in the apical membrane of the ileum and the colon 3, 6, 7) . A total of 55 mutations in SLC26A3 have been identified worldwide thus far 8) . The majority of mutation types are single nucleotide substitutions (55%), followed by small deletions/ insertions or their combinations (38%), large deletions (5%), and insertions (2%) 8) . These mutations result in defective absorption of Cl -and secretion of HCO3 -in the intestine, leading to Cl -rich watery diarrhea 3, 6, 7) . Because of this intestinal loss of ions and fluid, the patient experiences hypochloremia, hyponatremia, and dehydration. These conditions activate the reninangiotensin system, which causes both hypokalemia and metabolic alkalosis 3) . Accurate diagnosis and correction of electrolyte imbalance will restore normal growth and development with favorable prognosis. Recently, several drugs such as proton pump inhibitors and butyrate have been suggested as effective and successful therapies for diarrhea 3, 9, 10) . Here, we report a case of CCD in a preterm male infant with a mutation in the SLC26A3 gene who was successfully treated by oral administration of the proton pump inhibitor omeprazole.
CASE REPORT
A 30-year-old woman with a history of one pregnancy and one abortion was referred to our hospital at an estimated ges- reduced by inserting an orogastric tube for 3 days, the newborn received enteral nutrition. He was discharg ed at 9 days of age.
One week later, the newborn infant was admitted to hospi tal for icteric skin color and lethargic condition at 17 days of age.
Urine-like watery diarrhea about 10 times per day with insufficient sucking was also observed. In laboratory tests, hypona- Intravenous fluid therapy for electrolyte cor rection was discontinued and oral treatment with 3 mEq/kg/day sodium chloride (NaCl) was initiated. At the time of dis charge, the patient was able to take all formula feeds by mouth and serum electrolytes were stable after oral NaCl admini strations. After discharge, his serum electrolytes were within the normal range even though the amount of oral NaCl was reduced subsequently. At the same time, omeprazole treatment was continued and adjusted for his increased weight. . Other complications include preterm birth, severe polyhydramnios requiring therapeutic amniocentesis, and unnecessary surgery in neonates 3) . It is necessary to rule out intestinal obstruction, such as small bowel atresia or congenital megacolon, particularly when newborns present with delayed passage of meconium and distended abdomen 3, 11) .
The infant may have profuse watery diarrhea, which can be mistaken for urine, for several days. Due to this persistent watery diarrhea, dehydration and excessive weight loss will develop in patients with CCD. Metabolic alkalosis and electrolyte imbalance will be usually revealed in laboratory investi gations. If left untreated, these conditions can be fatal, as metabolic alkalosis and electrolyte imbalance can lead to arrhythmia and severe dehydration 3) . Untreated conditions may also result in developmental retardation, chronic kidney disease, and male subfertility 3) . The clinical characteristics and long-term outcomes of CCD cases reported in Korea are sum marized in Table 1 12 -16) .
Diagnosis of CCD is based on the measurement of high fecal chloride (>90 mmol/L) and acidic pH 3) . High concentration of fecal chloride is still sufficient to confirm the diagnosis. Currently, genetic analysis is available for the detection of CCDrelated SLC26A3 mutations and a total of 55 mutations have been reported 8) . In Korea, genetic analysis results of 8 CCD patients have been published, and it was suggested that c.2063-1G>T mutation could have been a founder mutation in Korean population 5) . Our case also demonstrated the presence of the homozygous c.2063-1G>T mutation in our patient con firming the above notion that it could be a genuine founder mutation.
From the therapeutic point of view, salt substitution therapy is the standard CCD treatment, while the management of acute . The combination therapy with both NaCl and potassium chloride (KCl) via the oral or intravenous route will protect against common CCD complications. The optimal dosage of chloride ranges from 6 to 8 mmol/kg/day in infants and from 3 to 4.4 mmol/kg/day in older children 3, 17) .
Several therapies for diarrhea have been recently suggested in several cases. Omeprazole, a proton pump inhibitor, has been found to reduce watery diarrhea 10) . Omeprazole de cre ases intestinal chloride loss by protecting endogenous chloride stores and by reducing the amount of chloride presented in the intestinal tract 10) . Butyrate, a short-chain fatty acid, was also used to alleviate watery diarrhea through the activation of a parallel Cl -/butyrate and Na + /H -exchanger 18) . In addition, cholestyramine decreased watery diarrhea symptoms to a certain extent, but its therapeutic action was moderate and trans ient 3) .
There have been several reported cases of CCD that were successfully treated with omeprazole. Fuwa et al. 19) used omeprazole and butyrate for reducing watery diarrhea and their patient displayed normal growth without electrolyte supplementation. Pieroni et al. 9) described a CCD patient who recei ved long-term omeprazole, which maintained serum electrolyte balance without NaCl and KCl supplementation. In our case, we also found that omeprazole strongly reduced watery diar rhea symptoms and corrected electrolyte im balance. How ever, close monitoring of the efficacy of and adverse reactions asso ciated with omeprazole is necessary because its utility and safety as an anti-diarrheal have not been sufficiently verified in CCD patients thus far. Because no official guidelines for omeprazole use in CCD patients have been published to date, we are planning manage diarrhea with omeprazole maintenance therapy and carefully monitor electrolyte imbalance and symp tom severity.
In conclusion, we have reported a case of CCD with a SLC26A3 mutation, which was successfully treated with omeprazole according to sugge stions in the literature. 
